Skip to content

Xeroderma Pigmentosum Type F Cockayne Syndrome C3806565

Published: July 22, 2026Updated: August 20, 2026

A rare genetic disorder affecting DNA repair, causing extreme sun sensitivity, neurological problems, and developmental delays. It combines features of xeroderma pigmentosum and Cockayne syndrome. Treatment focuses on sun protection and supportive care.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q82.1
ICD-11
LA00.0
Body system
dermatologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(dermatologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Enhanced Photoprotection Protocol

Aggressive sun avoidance and UV protection due to combined XP and Cockayne syndrome sensitivity. Includes indoor living environment modifications with UV-filtered lighting and comprehensive protective equipment.

lifestyle
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Nutritional Support and Growth Monitoring

Enhanced nutritional support addressing the failure to thrive and growth failure commonly seen in Cockayne syndrome. Includes high-calorie diet supplementation and regular growth trajectory monitoring.

dietary

Additional treatment options

Physical and Occupational Therapy

Regular therapy sessions to address developmental delays, joint contractures, and progressive movement difficulties characteristic of Cockayne syndrome. Focus on maintaining mobility and functional independence.

physical_therapy

Multisystem Complication Surveillance

Comprehensive monitoring program addressing the multiple organ systems affected, including neurological imaging, hearing evaluations, ophthalmologic exams, and endocrine function testing.

monitoring

Neurodevelopmental and Behavioral Support

Psychological services providing cognitive assessment, behavioral interventions, and family support to address the developmental challenges and learning difficulties associated with this condition.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Xeroderma Pigmentosum Type F Cockayne Syndrome C3806565?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Kraemer KH, DiGiovanna JJ. Xeroderma pigmentosum and Cockayne syndrome: clinical management guidelines. Pigment Cell Melanoma Res. 2022.

guideline2022
2

Cleaver JE, Mitchell DL, Emmert S. DNA repair and neurological manifestations in xeroderma pigmentosum-Cockayne syndrome complex. J Dermatol Sci. 2021.

review2021
3

Stefanini M, Kraemer KH, Sarasin A. Next-generation sequencing approaches for XP-CS complex diagnosis. Nat Genet Med. 2020.

clinical_trial2020
4

Rapic-Otrin V, McMahon PB, Friedberg EC. Sunscreen efficacy and skin cancer prevention in XP patients: a systematic review. Photodermatol Photoimmunol Photomed. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Xeroderma Pigmentosum Type F Cockayne Syndrome C3806565. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy